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Abstract
Neuroblastoma is the most common extracranial solid tumor in children. The co-
occurrence of neuroblastoma and acute lymphoblastic leukemia is rare. We report a rare
case of advanced-stage neuroblastoma in a 3.5-year-old girl that was accompanied by
acute lymphoblastic leukemia following treatment. Her leukemia may have been due
to chemotherapy (secondary leukemia) or may have been de novo.
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Introduction
Secondary leukemia, a well-
recognized late complication of
antineoplastic therapy, typically
manifests as acute myeloid leukemia
(AML).1 Secondary acute
lymphoblastic leukemia (SALL), a
rare disease, is defined as acute
lymphoblastic leukemia (ALL) that
occurs after another malignancy
irrespective of whether patients have
received prior therapy. Therapy-
related AML, or secondary leukemia,
is a well-recognized entity included
in the World Health Organization
classification.2 In one recent review,
ALL represented only 5% to 10% of
secondary leukemias.3
Here we present a case of
neuroblastoma associated with ALL.
Case Report
In December 2008, a 3.5-year-old
girl was admitted to our hospital due
to constipation and abdominal
bulging. At that time abdominal and
pelvic sonography could not evaluate
the upper pole of the left kidney due
to the presence of a heterogeneous
mixed-echo soft tissue structure
measuring 86×65 mm. The computed
tomography scan showed a massive
noncalcified tumor in the upper pole
of the left kidney that crossed the
midline.
A biopsy was performed and the
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pathological diagnosis was undifferentiated
neuroblastoma with poor stroma, mitosis and
karyorrhexis index MKI >200, unfavorable
Shimada histopathology and N-myc amplification
(22 copies). There was lymph node invasion by
neoplastic cells. Unfortunately, no computed
tomography images were available at the time of
writing. However, the diagnosis of neuroblastoma
appeared to be likely because of immunohisto-
chemical studies and imaging findings at the time
of diagnosis.
Immunohistochemical findings were positive
for synaptophysin, neuro-specific esterase and
chromographin A. The bone marrow was normal.
Because of these findings, she was considered to
be at high risk, and chemotherapy was initiated.
The chemotherapy regimen consisted of vincristin,
etoposide, cisplatin and cyclophosphamide.
Second-look surgery was done after five courses
of chemotherapy, which showed good response.
However, a meta-iodobenzylguanidine scan after
treatment was completed revealed multiple
abnormal collections of radioisotope in the right
supra-renal fossa that strongly suggested recurrent
tumor. The patient subsequently received two
courses of ifosfamide, carboplatin and etoposide
and was referred to a bone marrow transplant
center. Because of the lack of an appropriate
donor, we initiated the CCG-3891 protocol
(Children’s Cancer Group protocol for high-risk
neuroblastoma), which consisted of adriamycin,
cyclophosphamide, cisplatin and etoposide for
continued therapy. 
During a routine follow-up visit in April 2010,
she was found to be febrile and pale. Laboratory
analyses showed a leukocyte count of 7×109 µ/L,
hemoglobin 4 gr/dL and platelet count 6000×109
µ/L. Peripheral blood smear and bone marrow
aspirate showed many lymphoblasts with a high
nuclear/cytoplasmic ratio, compatible with ALL
(L1 morphology) (Fig. 1). Immunophenotype
was consistent with B- precursor ALL positive for
CD19 (79%), HLA–DR (80%) and CD10 (78%).
The child was treated with combination
chemotherapy that consisted of adriamycin,
vincristin, cyclophosphamide, prednisolone, L-
asparaginase and intrathecal therapy. On May 10,
2010, during chemotherapy, the patient died from
overwhelming sepsis. She received a total dose of
etoposide of about 3000 mg/ m2.
Discussion
Neuroblastoma, an embryonal tumor, is the
most common and deadly solid tumor of
childhood.4-6,12 These tumors have a
heterogeneous clinical presentation and course.4-
6,12 Some tumors progress rapidly to a fatal
outcome, and in other instances the tumors may
regress spontaneously in infants.4-6,12 The
treatment modalities for neuroblastoma are
surgery, chemotherapy and radiotherapy.4-6,10-13
Chemotherapy is the predominant modality of
management in intermediate and high-risk
neuroblastoma, and is also used in low-risk
patients with symptomatic involvement of vital
organs.5,6 In children with high-risk
neuroblastoma, the long-term survival rate is less
than 40% even with multimodal intensive therapy,
including hematopoietic stem cell transplanta-
tion.4,5,10,12
Many treatment protocols are available for
induction chemotherapy lasting 5 to 7 months.5
One of the induction chemotherapy regimens
currently in use consists of cyclophosphamide,
etoposide, adriamycin and cisplatin, which are
the active agents in the CCG-3891 regimen.4,5
The intensity of therapy required to successfully
treat high-risk neuroblastoma necessitates carefulFigure 1. Bone marrow aspirate showing many lymphoblasts with
a high nuclear / cytoplasmic ratio (Wright-Giemsa staining)
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consideration of the possible serious late
sequelae,12 and we recommend that bone marrow
aspiration be performed periodically in these
patients. 
Secondary myelodysplasia and AML have
been associated with certain chemotherapeutic
agents such as alkylating agents and topoisomerase
II inhibitors.4,5 The pathogenesis for secondary
ALL are not well defined. However, the
development of secondary ALL is related to DNA
topoisomerase II inhibitors. Alkylating agents
and topoisomerase II inhibitors have been
associated with secondary AML.4-6,11-13 In most
patients treated with alkylating agents, secondary
AML is preceded by myelodysplastic syndrome
(MDS) and is correlated with the total dose of
alkylating agents, with a latency period of 3.5 to
5.5 years.4,5 Topoisomerase II inhibitor-associated
leukemia does not have an MDS phase and
presents acutely.4,5,9
Providing appropriate health care for cancer
survivors is emerging as one of the major
challenges in medicine.4 Currently the overall
five year survival rate in childhood cancers is
75%–80%.4,5 Late effects are defined as any
physical or psychological outcome that develops
or persists beyond 5 years from the diagnosis of
cancer. Up to two thirds of childhood cancer
survivors are likely to experience at least one late
effect, with one fourth of all survivors
experiencing severe or life-threatening side
effects.4,5 Perhaps the most common serious late
adverse effect is the occurrence of secondary
cancers in patients successfully cured of a first
malignancy. The risk appears to be cumulative,
increasing by about 0.5% per year and resulting
in an approximately 12% incidence 25 years after
treatment. 
Childhood cancer survivors have 10 to 20
times the lifetime risk of second malignant
neoplasms compared with age-matched controls.
Secondary malignant neoplasms are the most
common cause of death in long-time survivors
after recurrence of the primary cancer.5 Shinsaku
et al. reported one case of ALL and one case of
mediastinal lymphoblastic lymphoma that
developed after treatment for neuroblastoma.
Additionally, Telma et al. reported 4-year-old boy
with a diagnosis of stage IV neuroblastoma who
was treated with six cycles of cyclophosphamide,
doxorubicin, cisplatin and etoposide for 12
months. The patient attained partial remission
and presented with a diagnosis of active
myelomonocytic leukemia, which was confirmed
by immunophenotyping.8 After 2 months of
treatment, the child died with both malignancies
active simultaneously.8
In a recent review of secondary ALL by Hunger
et al., two out of three patients with neuroblastoma
had received epipodophyllotoxins. Importantly,
one of the two patients tested had the
t(4;11)(q21;q23) chromosomal abnormality.3 Pui
et al. identified three cases of secondary ALL
with t(4;11) who had received epipodophyllotox-
ins for their primary malignancy.9 The prognosis
of secondary ALL appears to be dismal1,4,5 and
very few long-term survivors have been reported.5
The pathogenesis of secondary lymphoid
malignancy in patients with neuroblastoma is
uncertain.1 Allogenic hematopoietic stem cell
transplantation is the treatment of choice.4,5 Our
case is unique because SALL is a rare event. The
cause of ALL in our case was uncertain and might
have been related to previous treatment with
epipodophyllotoxins and cyclophosphamide or
host susceptibility, or may have been a chance
occurrence.
Conclusion
According to earlier studies, a neoplasm
appearing at least 2 years after a first tumor is
defined as secondary.4-6,11-16 So the occurrence of
two tumors in interval less than 2 years can be
regarded as simultaneous presence. In our patient,
ALL was diagnosed about 14 months after the
onset of neuroblastoma. Compared to other cases
in the literature, the cause of SALL in our patient
is less certain and may be related to previous
treatment with epipodophilodoxins and cyclophos-
phamide, or the presence of the t abnormality.4,11
Unfortunately, no cytogenetic study was done in
our patient. It should be emphasized that the
Concurrent Neuroblastoma and ALL
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CCG-3891 protocol includes etoposide and
cyclophosphamide, which are associated with
leukemogenic effects, and the most common
therapy-related leukemia is AML.4-6
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